Argenx SE (ARGX):企業の財務・戦略的SWOT分析

◆英語タイトル:Argenx SE (ARGX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH140762FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥78,600見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥117,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Argenx SE (Argenx) is a human antibodies developer. The company offers autoimmunity and oncology products. Its wholly owned product candidates include ARGX-113, ARGX-110, ARGX-117 and ARGX-111. Argenx partnered product candidates are ARGX-109, ARGX-112, ARGX-115 AND ARGX-116. The company offers treatment for T-cell lymphoma, nasopharyngeal cancer, chronic myelogenous leukemia and MET amplified cancer among others. It offers product such as Efgartigimod, Cusatuzumab and candidates to myasthenia gravis immune thromocytopeniapemphigus valgaris chronic auto immune diseases, T cell lymphoma, acute myeloid leukemia and blood cancer. Argenx products are used for the treatment of inflammatory and autoimmune diseases. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands and Belgium. Argenx is headquartered in Breda, the Netherlands.

Argenx SE Key Recent Developments

Mar 04,2021: argenx reports full year 2020 financial results and provides fourth quarter business update
Mar 04,2021: argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update argenx today reported financial results for the full year 2020 and provided a fourth quarter business update. Read
Feb 04,2021: argenx announces full exercise of underwriters option to purchase additional ADSs
Jan 11,2021: argenx to Present at 39th Annual J.P. Morgan Healthcare Conference argenx today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET. Re
Jan 07,2021: L2 : Business Expansions : argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China argenx SE and Zai Lab Limited today announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater Read

This comprehensive SWOT profile of Argenx SE provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Argenx SE including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Argenx SE – Key Information
Argenx SE – Overview
Argenx SE – Key Employees
Argenx SE – Key Employee Biographies
Argenx SE – Key Operational Heads
Argenx SE – Major Products and Services
Argenx SE – History
Argenx SE – Company Statement
Argenx SE – Locations And Subsidiaries
Argenx SE
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Argenx SE – Business Description
Argenx SE – Corporate Strategy
Argenx SE – SWOT Analysis
SWOT Analysis – Overview
Argenx SE – Strengths
Argenx SE – Weaknesses
Argenx SE – Opportunities
Argenx SE – Threats
Argenx SE – Key Competitors

Section 3 – Company Financial Performance Charts

Argenx SE – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Argenx SE, Key Information
Argenx SE, Key Ratios
Argenx SE, Share Data
Argenx SE, Major Products and Services
Argenx SE, History
Argenx SE, Key Employees
Argenx SE, Key Employee Biographies
Argenx SE, Key Operational Heads
Argenx SE, Other Locations
Argenx SE, Subsidiaries
Argenx SE, Key Competitors
Argenx SE, SWOT Analysis
Argenx SE, Ratios based on current share price
Argenx SE, Annual Ratios
Argenx SE, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Argenx SE (ARGX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Holland Colours NV (HOLCO):企業の財務・戦略的SWOT分析
    Holland Colours NV (HOLCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Wentworth Resources Ltd (WRL):企業の財務・戦略的SWOT分析
    Wentworth Resources Ltd (WRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Saudi Arabian Oil Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Saudi Arabian Oil Co (Saudi Aramco) is an integrated energy and chemcials company. It is a state-owned enterprise that carries out exploration, production and processing of crude oil and natural gas, refining, fractionation of natural gas, production of petrochemicals, and distribution of pe …
  • Vigor Shipyards, Inc:企業の戦略・SWOT・財務分析
    Vigor Shipyards, Inc - Strategy, SWOT and Corporate Finance Report Summary Vigor Shipyards, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Recipharm AB:企業のM&A・事業提携・投資動向
    Recipharm AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Recipharm AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Success Universe Group Limited
    Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report Summary Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Victoria’s Secret Stores, LLC:企業の戦略・SWOT・財務情報
    Victoria's Secret Stores, LLC - Strategy, SWOT and Corporate Finance Report Summary Victoria's Secret Stores, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • InsuLine Medical Ltd (INSL)-医療機器分野:企業M&A・提携分析
    Summary InsuLine Medical Ltd (InsuLine Medical) is a medical device company that develops, manufactures and markets device which enables patients on intensive insulin therapy. The company’s products include InsuPad and InsuPatch. Its InsuPad is a patch for syringes and insulin pens; and InsuPatch is …
  • Grupo Financiero Galicia S.A. (GGAL3):企業の財務・戦略的SWOT分析
    Grupo Financiero Galicia S.A. (GGAL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • The Tata Power Company Limited:企業の戦略・SWOT・財務情報
    The Tata Power Company Limited - Strategy, SWOT and Corporate Finance Report Summary The Tata Power Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Admedes GmbH:企業の戦略的SWOT分析
    Admedes GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Sumitomo Dainippon Pharma Co., Ltd.:企業の戦略・SWOT・財務分析
    Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Jardine Cycle & Carriage Limited:企業の戦略・SWOT・財務分析
    Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Synthetic Biologics Inc (SYN):企業の財務・戦略的SWOT分析
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • HSBC Holdings Plc:企業のM&A・事業提携・投資動向
    HSBC Holdings Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HSBC Holdings Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Cavco Industries Inc:企業の戦略・SWOT・財務情報
    Cavco Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Cavco Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • SELEX Galileo Inc.:企業の戦略・SWOT・財務分析
    SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report Summary SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Genfit SA (GNFT)-医療機器分野:企業M&A・提携分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s product pipeline comprise GFT505, TGFTX1, TGFTX3, TGFTX4, TGFTX5 and SAN/GFT-2. Its TGFTX1 can be …
  • Confo Therapeutics:製薬・医療:M&Aディール及び事業提携情報
    Summary Confo Therapeutics is a drug discovery company that conducts research and development of g protein coupled receptors targeted therapeutics. The company offers CONFO body technology. Its technology uses confobody stabilized functional conformations of g protein coupled receptors. Confo Therap …
  • Harvard Bioscience Inc (HBIO):企業の財務・戦略的SWOT分析
    Harvard Bioscience Inc (HBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆